Because of the low incidence of ovarian germ cell tumors, their chemotherapy regimens have arisen largely based on studies of chemotherapy regimens for testicular cancer. Over the past 40 years, chemotherapy regimens for ovarian malignant germ cell tumors have undergone an evolution from VAC (vincristine + actinomycin-D + cyclophosphamide) to PVB (cisplatin + vincristine + bleomycin or paxillomycin) to BEP (bleomycin + etoposide + cisplatin), and their survival rates have improved dramatically, with surgery in combination with chemotherapy becoming the basic paradigm of MOGCT treatment .. The choice of chemotherapy regimen after fertility preservation surgery should take into account both the therapeutic efficacy and its impact on ovarian function and offspring. The number of chemotherapy sessions depends on the pathological stage, histological type, residual tumor size, tumor marker decline, etc. The 2013 NCCN Guidelines for Ovarian Cancer state that: Stage I anaplastic tumors and immature teratomas of G1 grade in Stage Ia have a better prognosis, and can be followed up and observed after surgery; all other stages and types of MOGCT tumors should receive adjuvant chemotherapy after surgery. BEP regimen is recommended as the first choice of chemotherapy: bleomycin 30U/wk, etoposide 100mg/m2/d, d1~5, cisplatin 20mg/m2/d, d1~5, 3~4 cycles of chemotherapy. Because bleomycin has irreversible pulmonary fibrosis effect, it is recommended that pulmonary function tests be performed before and after treatment, and the lifetime dose should not exceed 250 mg/m2. Because anaplastic tumors have a better prognosis than other types, in order to reduce toxicity and side-effects, for certain patients with stage IB~III anaplastic tumors, a 3-cycle EP regimen may be considered to be given: carboplatin 500mg, d1, etoposide 120mg/m2 , d1~3, with 1 cycle every 4 weeks. The chemotherapy regimen for refractory or recurrent patients is still controversial and needs to be further explored in large-sample case-control studies.Weinberg et al[7] summarized 27 postoperative chemotherapy in 40 patients, of which 23 used BEP regimen and 3 relapsed.The chemotherapy regimen of choice for the relapse was the VAC and VIP (vincristine + isocyclophosphamide + cisplatin) regimen, with an overall survival rate of 100%. Cicin [28] et al. analyzed the prognosis of 32 cases of yolk sac tumors, all but 1 of the 10 cases recurred within 2 years, only 1 case was in remission by BEP rescue chemotherapy, 5 cases did not respond to chemotherapy, 3 cases were still found to have residual tumors, and 1 case died due to chemotherapy side effects. Some authors [[i]] reported patients with anaplastic cell tumors, recurring 2 years after unilateral adnexectomy, had no remission with chemotherapy using the BEP regimen, and changed to the VIP regimen for remission after 6 courses of chemotherapy. For MOGCT patients, BEP or BVP is the preferred chemotherapy regimen, which has not been found to have a significant effect on ovarian function, Yoo et al [[ii]] summarized 9 premenstrual and 16 pubertal patients out of 25 MOGCTs, all of whom underwent fertility preservation surgery, 17 patients received BEP in combination with chemotherapy, and 8 out of the 9 premenstrual patients subsequently had normal menstruation. Of the 16 adolescent patients, 15 returned to normal menstruation and 1 patient developed premature ovarian failure. There is growing evidence to support the use of GnRH agonists during chemotherapy as a proven treatment for preservation of ovarian function.Megan et al. [[iii]] statistically analyzed nine case-control studies on the treatment of preservation of ovarian function during chemotherapy in patients with Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, and breast cancer.178 patients were treated with GnRHa during chemotherapy, and 93% of them maintained ovarian function. GnRHa was used during chemotherapy in 178 patients, and 93% of them maintained ovarian function. In contrast, only 48% of the 188 patients treated without GnRHa during chemotherapy maintained ovarian function. It was concluded that GnRH agonists appeared to improve ovarian function and fertility in post-chemotherapy patients. There are few clinical studies on the protection of ovarian function. Most of the studies using GnRH are laboratory animal experiments. the number of cases of premature ovarian failure and amenorrhea in MOGCT patients after chemotherapy is very small, and whether GnRH can effectively reduce its occurrence still needs to be confirmed by more clinical randomized controlled trials. Weinberg et al [7] used oral contraceptives during chemotherapy in 16 patients after fertility preservation surgery, and all of them resumed normal menstruation after the end of chemotherapy, and concluded that oral contraceptives could be used for ovarian protection during chemotherapy pairs. The adverse effects of oral contraceptives on pre-pubertal patients have not yet been clarified, so further studies are needed to confirm this treatment measure.